GeneLancet is a gene editing company that has developed proprietary LgRNA technology, which enables precise gene editing with ultra-pure, high quality ligated single molecule guide RNAs (LgRNA). LgRNAs have enhanced activity at challenging targeting sites.
GeneLancet is developing LgRNA-conjugates-directed CRISPR gene editing. Our platform provides significant benefits in developing therapeutics for rare monogenic conditions, cancer, viral infectious diseases and other diseases with significant unmet needs.